Universal approach could potentially expand CAR T cell therapy to all blood cancers

A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer.

Related Keywords

,Lily Ramsey ,Saar Gill ,Nils Wellhausen ,National Institutes Of Health ,Perelman School Of Medicine ,University Of Pennsylvania ,Parker Institute For Cancer Immunotherapy ,Perelman School ,Science Translational Medicine ,Carl June ,National Institutes ,Parker Institute ,Blood ,Fell ,Immunotherapy ,Blood Cancer ,One ,Bone Marrow ,Dancer ,Rispr ,Efficacy ,Hematology ,Hospital ,Immune System ,Leukemia ,Medicine ,Olecule ,Ncology ,Reclinical ,Protein ,Research ,Stem Cells ,Transplant ,